{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:33:54Z","timestamp":1777937634526,"version":"3.51.4"},"reference-count":13,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.7883\/yoken.jjid.2025.286","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:09:57Z","timestamp":1777500597000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Mumps-specific Neutralizing Antibody Compared to Immunoglobulin G Antibody in Japanese Children After the Coronavirus Disease Pandemic"],"prefix":"10.7883","author":[{"given":"Tomohiro","family":"Oishi","sequence":"first","affiliation":[{"name":"Department of Clinical Infectious Diseases, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuho","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Virus, Osaka Institute of Public Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Virus, Osaka Institute of Public Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kawasaki Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1. Mumps (infectious parotitis) in Japan, as of September 2016. IASR 37: 185-186, October, 2016. Available at <https:\/\/www.niid.go.jp\/niid\/en\/iasr-vol37-e\/865-iasr\/6843-te.html> Accessed Jan 9, 2025."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Stanley A Plotkin. Commentary: Mumps vaccines: do we need a new one? Pediatr Infect Dis J. 2013 Apr;32(4):381-2. doi: 10.1097\/INF.0b013e3182809dda.","DOI":"10.1097\/INF.0b013e3182809dda"},{"key":"3","doi-asserted-by":"crossref","unstructured":"2. Rubin SA, Link MA, Sauder CJ, et al. Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012;86:615-620.","DOI":"10.1128\/JVI.06125-11"},{"key":"4","doi-asserted-by":"crossref","unstructured":"3. Brown WF. Vaccine estimation in the Reed-Muench fifty percent end-point determination. Am J Hyg. 1964:79:37-46.","DOI":"10.1093\/oxfordjournals.aje.a120362"},{"key":"5","doi-asserted-by":"crossref","unstructured":"4. Reed-Muench. Fifty Percent End-Point Determination. Arch Exp Path Pharmak. 1931;162:480-483. https:\/\/doi.org\/10.1007\/BF01863914","DOI":"10.1007\/BF01863914"},{"key":"6","doi-asserted-by":"crossref","unstructured":"5. Hilleman MR, Weibel RE, Buynak EB, et al. Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. N Engl J Med. 1967;276:252-258.","DOI":"10.1056\/NEJM196702022760502"},{"key":"7","doi-asserted-by":"crossref","unstructured":"6. Weibel RE, Stokes J Jr, Buynak EB, et al. Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. N Engl J Med. 1967;276:245-251.","DOI":"10.1056\/NEJM196702022760501"},{"key":"8","doi-asserted-by":"crossref","unstructured":"7. Sowers SB, Clemmons NS, Mercader S, et al. Identifying a level of neutralizing antibody that correlates with protection from clinical mumps disease during a 2017 mumps outbreak among military service members. Open Forum Infect Dis. 2024;11:ofae329.","DOI":"10.1093\/ofid\/ofae329"},{"key":"9","doi-asserted-by":"crossref","unstructured":"8. Cortese MM, Barskey AE, Tegtmeier GE, et al. Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity. J Infect Dis. 2011;204:1413-1422.","DOI":"10.1093\/infdis\/jir526"},{"key":"10","unstructured":"9. Centers for Disease Control and Prevention. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013. Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1-34."},{"key":"11","doi-asserted-by":"crossref","unstructured":"10. Mauldin J, Carbone K, Hsu H, et al. Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays. J Clin Microbiol. 2005;43:4847-4851.","DOI":"10.1128\/JCM.43.9.4847-4851.2005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"11. Rasheed MAU, Hickman CJ, McGrew M, et al. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood. Proc Natl Acad Sci U S A. 2019;116:19071-19076.","DOI":"10.1073\/pnas.1905570116"},{"key":"13","doi-asserted-by":"crossref","unstructured":"12. Narita M, Matsuzono Y, Takekoshi Y, et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol. 1998;5:799-803.","DOI":"10.1128\/CDLI.5.6.799-803.1998"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2025.286\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:11:57Z","timestamp":1777695117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2025.286\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2025.286","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"JJID.2025.286"}}